BiotechTube

Epoetin Alfa

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia

Trial Timeline

Mar 1, 2002 → Aug 1, 2005

NCT ID
NCT00211120

About Epoetin Alfa

Epoetin Alfa is a approved stage product being developed by Johnson & Johnson for Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00211120. Target conditions include Anemia.

What happened to similar drugs?

20 of 20 similar drugs in Anemia were approved

Approved (20) Terminated (4) Active (0)
✅Aranesp®AmgenApproved
✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved
✅Roxadustat + rHuEPOAstraZenecaApproved
✅ICL670 + Chelation + No chelationNovartisApproved
✅cera, darbepoetin, epoetin-beta + ESARocheApproved
✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved
✅epoetin beta [NeoRecormon]RocheApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT00270010Phase 2Completed
NCT00266617Phase 2Completed
NCT00002022Pre-clinicalCompleted
NCT00269984Phase 2Completed
NCT00269945Phase 2Completed
NCT00270114Phase 2/3Completed
NCT00446602Phase 2Withdrawn
NCT00270179Phase 3Completed
NCT00269997Phase 2Completed
NCT00270023Phase 2/3Completed
NCT00270270Phase 2Completed
NCT00337935Phase 2Completed
NCT00306267Phase 2Terminated
NCT00641589Phase 1Completed
NCT00246298Phase 2Terminated
NCT00212875Phase 2Completed
NCT00236405Phase 2Terminated
NCT00240734Phase 2Terminated
NCT00210587Phase 3Completed
NCT00236678Phase 2Terminated

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40